Opinion|Videos|September 30, 2024
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Key Takeaways
- NMIBC management includes TURBT and intravesical therapy, with BCG as a key treatment for higher-risk patients.
- BCG treatment stimulates an immune response, enhancing the body's ability to target bladder cancer cells.
Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the standard treatment options for non–muscle-invasive bladder cancer (NMIBC)?
- What are the management options for patients with intermediate and high-risk NMIBC?
- Can you explain the mechanism of action of BCG treatment in stimulating the immune response against bladder cancer?
- In an ideal treatment paradigm with single-agent BCG, what are the best outcomes for patients with high-risk NMIBC?
- What are the rates of recurrence and progression?
- What do you feel the rates of progression are in the real world vs what you see in your practice?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
